Complement Inactivating Agents
"Complement Inactivating Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that negatively regulate the cascade process of COMPLEMENT ACTIVATION. Uncontrolled complement activation and resulting cell lysis is potentially dangerous for the host.
Descriptor ID |
D051056
|
MeSH Number(s) |
D27.505.696.477.656.500
|
Concept/Terms |
Complement Inactivating Agents- Complement Inactivating Agents
- Agents, Complement Inactivating
- Inactivating Agents, Complement
- Complement Inhibitors
- Inhibitors, Complement
- Complement Inhibiting Agents
- Agents, Complement Inhibiting
- Inhibiting Agents, Complement
|
Below are MeSH descriptors whose meaning is more general than "Complement Inactivating Agents".
Below are MeSH descriptors whose meaning is more specific than "Complement Inactivating Agents".
This graph shows the total number of publications written about "Complement Inactivating Agents" by people in this website by year, and whether "Complement Inactivating Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2007 | 0 | 1 | 1 |
2010 | 1 | 1 | 2 |
2011 | 1 | 1 | 2 |
2012 | 2 | 0 | 2 |
2013 | 1 | 0 | 1 |
2014 | 1 | 1 | 2 |
2015 | 1 | 0 | 1 |
2016 | 2 | 0 | 2 |
2017 | 2 | 0 | 2 |
2018 | 2 | 0 | 2 |
2020 | 1 | 1 | 2 |
2021 | 5 | 2 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Complement Inactivating Agents" by people in Profiles.
-
Characterization of Novel P-Selectin Targeted Complement Inhibitors in Murine Models of Hindlimb Injury and Transplantation. Front Immunol. 2021; 12:785229.
-
In Situ Pre-Treatment of Vascularized Composite Allografts With a Targeted Complement Inhibitor Protects Against Brain Death and Ischemia Reperfusion Induced Injuries. Front Immunol. 2021; 12:630581.
-
Chronic complement dysregulation drives neuroinflammation after traumatic brain injury: a transcriptomic study. Acta Neuropathol Commun. 2021 07 19; 9(1):126.
-
Increasing the efficacy and safety of a human complement inhibitor for treating post-transplant cardiac ischemia reperfusion injury by targeting to a graft-specific neoepitope. J Heart Lung Transplant. 2021 10; 40(10):1112-1121.
-
Natural immunoglobulin M-based delivery of a complement alternative pathway inhibitor in mouse models of retinal degeneration. Exp Eye Res. 2021 06; 207:108583.
-
Subretinal Rather Than Intravitreal Adeno-Associated Virus-Mediated Delivery of a Complement Alternative Pathway Inhibitor Is Effective in a Mouse Model of RPE Damage. Invest Ophthalmol Vis Sci. 2021 04 01; 62(4):11.
-
A novel injury site-natural antibody targeted complement inhibitor protects against lung transplant injury. Am J Transplant. 2021 06; 21(6):2067-2078.
-
Complement-Mediated Microglial Phagocytosis and Pathological Changes in the Development and Degeneration of the Visual System. Front Immunol. 2020; 11:566892.
-
The use of Matrigel combined with encapsulated cell technology to deliver a complement inhibitor in a mouse model of choroidal neovascularization. Mol Vis. 2020; 26:370-377.
-
Tissue-targeted complement therapeutics. Mol Immunol. 2018 10; 102:120-128.